Compared with MVA alone and placebo, it induces more peripheral CD8+ TSCM cells and a higher level of CD8+ T cell-mediated inhibition of the replication of different HIV-1 branches can respond to acute HIV infection or effectively control the chronic replication of HIV (152). This evidence concerns the gene CD8A and HIV infectious disease.